睿知中国医院研究地图
候选清单

正在招募乳腺癌I/II期

登记标题,引自 ClinicalTrials.gov(英文原文,暂无中文译文)

GB268 Monotherapy or Combination Therapy for Locally Advanced/Metastatic Breast Cancer (Phase Ib/Ⅱ)

ClinicalTrials.gov 上登记的一项乳腺癌开放试验。牵头方不是本站收录的医院;本站收录的 1 家医院列为研究中心。

状态、分期和开始时间依据 ClinicalTrials.gov 在 2026年11月18日 的登记,登记库此后可能已有更新。能否参加由研究团队决定。不构成医疗建议。

研究团队的联系方式见登记记录。本站不转递咨询。

列出这项试验的中国大陆医院 1

登记记录中列为牵头方或研究中心、且为本站收录的医院(研究中心为开放状态)。牵头方在前,研究中心按英文名称字母排序。

  1. 研究中心中国医学科学院肿瘤医院National Cancer Center / Cancer Hospital, CAMS北京医院页面

登记记录可能还列有其他研究中心(包括中国大陆以外),各中心在试验期间也可能开放或关闭。在 ClinicalTrials.gov 查看全部研究中心

来源:ClinicalTrials.gov 登记记录 NCT07738341,读取于 2026年11月18日;医院名称与本站医院名单匹配。 名称如何匹配

这项试验的核对清单 7

只列这项试验的登记记录有明确答案的要点:登记的年龄和性别,以及写明数值、评分、分期或具体检查的标准条目。与医疗资料对照后可勾选。条目为英文原文,暂无中文译文。

展开清单(7 项)收起清单
  1. 18 岁 至 未注明;性别:不限

    登记记录的入选字段

  2. Histologically confirmed locally advanced unresectable or metastatic breast cancer (Triple-Negative Breast Cancer [TNBC] or Hormone Receptor-Positive/Human Epidermal Growth Factor Receptor 2-Negative [HR+/HER2-]).

    入选标准第 2 条

  3. No prior treatment with any immune checkpoint inhibitor (e.g., anti-Programmed Death-1 [PD-1], anti-Programmed Death-Ligand 1 [PD-L1], anti-Cytotoxic T-Lymphocyte-Associated Protein 4 [CTLA-4]) or Programmed Death-1/Vascular Endothelial Growth Factor [PD-1/VEGF] bispecific antibody, except for adjuvant therapy if relapse occurred ≥12 months after discontinuation.

    入选标准第 4 条

    Unresolved toxicity from prior therapy > Grade 1 (except alopecia or Grade ≤2 hypothyroidism stable on hormone replacement).

    排除标准第 4 条

    Prior immune-related adverse events [irAEs] ≥ Grade 3 leading to treatment discontinuation.

    排除标准第 5 条

  4. Eastern Cooperative Oncology Group [ECOG] performance status 0 or 1.

    入选标准第 6 条

  5. At least one measurable lesion per Response Evaluation Criteria in Solid Tumors version 1.1 [RECIST v1.1].

    入选标准第 3 条

  6. History of other malignancies within 3 years (except cured non-melanoma skin cancer or carcinoma in situ).

    排除标准第 7 条

    Positive for Hepatitis B Virus [HBV] surface antigen [HBsAg] or core antibody [HBcAb] with HBV-Deoxyribonucleic Acid [DNA] > 500 IU/mL; or positive Hepatitis C Virus [HCV] antibody with HCV-Ribonucleic Acid [RNA] above the lower limit of quantification.

    排除标准第 19 条

    Known primary immunodeficiency or positive Human Immunodeficiency Virus [HIV] antibody.

    排除标准第 20 条

  7. Pregnant or breastfeeding women.

    排除标准第 22 条

勾选只留在本页面,不保存、不发送。各项都符合也不等于能够参加,由研究团队经筛查后决定。需要研究团队判断的条目(如 “sufficient organ function”)不在此清单中,见下方完整标准。 本记录没有明确写出:分期或严重程度(按试验的定义);化验:血常规、肝肾功能。

需要向研究团队确认的问题

按固定关键词规则从登记记录中选出(非 AI,未经人工核对),引自 ClinicalTrials.gov, NCT07738341,读取于 2026年11月10日。

登记的入选标准

依据 ClinicalTrials.gov 的登记,读取于 2026年11月10日,未删减。以下为英文原文,暂无中文译文。符合书面条件并不等于能够参加,由研究团队经筛查后决定。

入选标准:Inclusion Criteria:

  1. Age ≥ 18 years, male or female.
  2. Histologically confirmed locally advanced unresectable or metastatic breast cancer (Triple-Negative Breast Cancer [TNBC] or Hormone Receptor-Positive/Human Epidermal Growth Factor Receptor 2-Negative [HR+/HER2-]).
  3. At least one measurable lesion per Response Evaluation Criteria in Solid Tumors version 1.1 [RECIST v1.1].
  4. No prior treatment with any immune checkpoint inhibitor (e.g., anti-Programmed Death-1 [PD-1], anti-Programmed Death-Ligand 1 [PD-L1], anti-Cytotoxic T-Lymphocyte-Associated Protein 4 [CTLA-4]) or Programmed Death-1/Vascular Endothelial Growth Factor [PD-1/VEGF] bispecific antibody, except for adjuvant therapy if relapse occurred ≥12 months after discontinuation.
  5. Assessed by the investigator as suitable for the assigned combination therapy.
  6. Eastern Cooperative Oncology Group [ECOG] performance status 0 or 1.
  7. Life expectancy ≥ 3 months.
  8. Adequate organ function (within 14 days before first dose, without transfusion or Granulocyte Colony-Stimulating Factor [G-CSF] support): Hemoglobin ≥ 9 g/dL, Absolute Neutrophil Count [ANC] ≥ 1.5×10\^9/L, Platelets ≥ 100×10\^9/L; Aspartate Aminotransferase [AST] and Alanine Aminotransferase [ALT] ≤ 3×Upper Limit of Normal [ULN] (≤5×ULN if liver metastases); Alkaline Phosphatase [ALP] ≤ 2.5×ULN (≤5×ULN if bone or liver metastases); Total Bilirubin ≤ 1.5×ULN (≤3×ULN for Gilbert's Syndrome); Serum Creatinine ≤ 1.5×ULN or Creatinine Clearance ≥ 50 mL/min (Cockcroft-Gault formula); Urine protein dipstick ≤ 1+ (if ≥2+, 24-hour urine protein quantification < 1 g); Coagulation function: International Normalized Ratio [INR] or activated Partial Thromboplastin Time [aPTT] ≤ 1.5×ULN (for patients not on anticoagulation therapy).
  9. Provide a Formalin-Fixed Paraffin-Embedded [FFPE] tumor tissue sample for biomarker testing.
  10. Effective contraception for fertile participants.

排除标准:Exclusion Criteria:

  1. Prior anti-cancer therapy within specified washout periods.
  2. Systemic immunosuppressive therapy within 2 weeks before first dose.
  3. Major surgery or significant traumatic injury within 4 weeks before first dose.
  4. Unresolved toxicity from prior therapy > Grade 1 (except alopecia or Grade ≤2 hypothyroidism stable on hormone replacement).
  5. Prior immune-related adverse events [irAEs] ≥ Grade 3 leading to treatment discontinuation.
  6. Active Central Nervous System [CNS] metastases (except stable asymptomatic lesions).
  7. History of other malignancies within 3 years (except cured non-melanoma skin cancer or carcinoma in situ).
  8. Uncontrolled pleural effusion or ascites requiring repeated drainage.
  9. Clinically significant cardiovascular disease (e.g., myocardial infarction, unstable angina, stroke within 6 months; QTcF prolongation; New York Heart Association [NYHA] Class II-IV heart failure; pericarditis/myocarditis).
  10. History of Interstitial Lung Disease [ILD] or non-infectious pneumonitis requiring steroids.
  11. Active or history of autoimmune disease requiring systemic treatment in the past 2 years.
  12. History of inflammatory bowel disease (e.g., Crohn's disease, ulcerative colitis, or chronic diarrhea).
  13. History of hypertensive crisis or hypertensive encephalopathy.
  14. Severe coagulation disorders or significant bleeding risk (e.g., severe vascular disease, hemoptysis, intracranial/spinal hemorrhage, tumor invading major vessels).
  15. History of abdominal fistula, gastrointestinal perforation, or intra-abdominal abscess.
  16. Active infection requiring systemic anti-infective therapy within 2 weeks; severe infection within 4 weeks.
  17. Uncontrolled intercurrent illness (e.g., poorly controlled hypertension or Type 2 diabetes mellitus).
  18. Known active tuberculosis [TB].
  19. Positive for Hepatitis B Virus [HBV] surface antigen [HBsAg] or core antibody [HBcAb] with HBV-Deoxyribonucleic Acid [DNA] > 500 IU/mL; or positive Hepatitis C Virus [HCV] antibody with HCV-Ribonucleic Acid [RNA] above the lower limit of quantification.
  20. Known primary immunodeficiency or positive Human Immunodeficiency Virus [HIV] antibody.
  21. History of solid organ or hematopoietic stem cell transplantation (except corneal transplant).
  22. Pregnant or breastfeeding women.
  23. Known hypersensitivity to GB268 or its excipients; history of severe hypersensitivity to other monoclonal antibodies.
  24. Any other condition that would make the participant unsuitable for the study.
  25. History of severe hypersensitivity to other drugs in the combination regimen.

引自 ClinicalTrials.gov, NCT07738341, 参与标准,读取于 2026年11月10日。

这些信息从哪里来

登记记录

ClinicalTrials.gov(美国国家医学图书馆),登记记录 NCT07738341,读取于 2026年11月18日。总体状态为正在招募、即将招募或邀请入组、且至少有一家列出医院的研究中心开放的试验,在本站有单独页面。仅在中国临床试验注册中心(ChiCTR)登记的试验没有计入。

疾病与医院

本站在 ClinicalTrials.gov 按疾病检索中国的试验,检索到这项试验,就把它列在该病下。登记记录中的牵头方和研究中心名称与本站医院名单匹配(ROR 编号与核对过的别名)。 定义

没有收录的内容

登记记录中研究者和联系人的姓名,以及记录之外的任何信息。标题和入选标准引自登记记录。

提出更正ClinicalTrials.gov NCT07738341